BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/18/2016 9:50:00 AM | Browse: 399 | Download: 377
Publication Name World Journal of Methodology
Manuscript ID 23800
Country/Territory United States
2015-12-17 16:47
Peer-Review Started
2015-12-23 14:18
To Make the First Decision
2016-01-14 17:08
Return for Revision
2016-01-18 14:21
2016-01-26 00:00
Second Decision
2016-01-31 11:52
Accepted by Journal Editor-in-Chief
2016-01-31 19:31
Accepted by Company Editor-in-Chief
2016-02-17 15:21
Articles in Press
2016-02-17 15:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-03-08 10:18
Publish the Manuscript Online
2016-03-18 09:50
ISSN 2222-0682 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity
Manuscript Source Invited Manuscript
All Author List Jun Gong, Esha Sachdev, Alain C Mita and Monica M Mita
Funding Agency and Grant Number
Corresponding author Monica M Mita, MD, Co-director, Division of Experimental Therapeutics Program, Samuel Oschin Compre­hensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, SCCT Mezzanine MS 35, Los Angeles, CA 90048, United States. monica.mita@cshs.org
Keywords Reovirus; Type 3 Dearing; Oncolytic virus; Ras; Epidermal growth factor receptor; Clinical trial; Preclinical; Immune modulation
Core Tip Reovirus has demonstrated oncolysis or preferential replication in cancer cells. The anticancer activity of reovirus has been demonstrated across a spectrum of malignancies in the preclinical setting. The relatively tolerable toxicity profile of reovirus renders it an attractive agent as part of combination therapy in cancer treatment. Reovirus-mediated immune modu-lation contributes to its antitumor activity via innate and adaptive immune responses and renders it an attractive component of immunotherapy. Here we compile the most extensive list of clinical trials investigating the anticancer efficacy of reovirus to date.
Publish Date 2016-03-18 09:50
Citation Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol 2016; 6(1): 25-42
Url http://www.wjgnet.com/2222-0682/full/v6/i1/25.htm
DOI http://dx.doi.org/10.5662/wjm.v6.i1.25
Full Article (PDF) WJM-6-25.pdf
Full Article (Word) WJM-6-25.doc
Manuscript File 23800-Review.doc
Answering Reviewers 23800-Answering reviewers.pdf
Audio Core Tip 23800-Audio core tip.MP3
Conflict-of-Interest Disclosure Form 23800-Conflict-of-interest statement.pdf
Copyright License Agreement 23800-Copyright assignment.pdf
Peer-review Report 23800-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 23800-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 23800-Scientific misconduct check.pdf
Scientific Editor Work List 23800-Scientific editor work list.pdf